4-(3-carbamoylpiperidino)piperidine | 184969-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-carbamoylpiperidino)piperidine
• 英文别名: 1-piperidin-4-ylpiperidine-3-carboxamide
• CAS: 184969-07-1
• 化学式: C₁₁H₂₁N₃O
• 分子量: 211.307
• InChiKey: ULPCXODSICRGMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-5-formyl-2(Z)-pentanone O-methyl-oxime 、 4-(3-carbamoylpiperidino)piperidine 在 2,2,2-三氟乙醇 、 3 A molecular sieve 、 sodium cyanoborohydride 作用下， 生成 1-[1-[(4Z)-5-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-4-methoxyiminopentyl]piperidin-4-yl]piperidine-3-carboxamide
  参考文献：
  名称：

  Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors

  摘要：

  The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00702-2
• 作为产物：
  描述：

  3-哌啶甲酰胺 在 palladium on activated charcoal 2,2,2-三氟乙醇 、 3 A molecular sieve 、 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 4-(3-carbamoylpiperidino)piperidine
  参考文献：
  名称：

  Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors

  摘要：

  The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00702-2

文献信息

• PYRIMIDINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1595869A1

  公开（公告）日：2005-11-16

  The present invention provides a pyrimidine derivative represented by Formula (I) [wherein Ar represents substituted or unsubstituted aryl, etc., R1 represents -NR2R3 (wherein R2 represents a hydrogen atom or substituted or unsubstituted lower alkyl and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, etc.), etc. A represents a single bond, Formula (III) (wherein m1 represents an integer of 0 to 2, n1 represents an integer of 0 to 4, a1 represents a number ranging from 0 to a substitutable number, R5 represents substituted or unsubstituted lower alkyl, etc. and each R5 may be the same or different when a1 is 2 or more), etc. and Q represents -NR6R7 (wherein R6 and R7 may be the same or different and each represents a hydrogen atom, a substituted or unsubstituted heteroalicyclic group, etc.), a substituted or unsubstituted heteroalicyclic group, substituted or unsubstituted piperidin-4-ylamino, etc.], or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof which have anti-inflammatory activities, modulating activities on TARC and/or MDC functions and the like, and are useful for treating and/or preventing diseases which is related to T cells such as allergic diseases, autoimmune diseases, transplant rejection, etc.

  本发明提供了一种由式（I）表示的嘧啶衍生物[其中Ar代表取代或未取代的芳基等，R1代表-NR2R3（其中R2代表氢原子或取代或未取代的较低烷基，R3代表取代或未取代的较低烷基、取代或未取代的芳基烷基等），等。A代表单键，式（III）（其中m1代表0至2的整数，n1代表0至4的整数，a1代表从0到可取代数的数字，R5代表取代或未取代的较低烷基等，每个R5在a1为2或更多时可以相同或不同），等，Q代表-NR6R7（其中R6和R7可以相同或不同，且每个代表氢原子、取代或未取代的杂环烷基等），取代或未取代的杂环烷基，取代或未取代的哌啶-4-基氨基等]，或其季铵盐，或其药用可接受盐，具有抗炎活性、调节TARC和/或MDC功能等，适用于治疗和/或预防与T细胞相关的疾病，如过敏性疾病、自身免疫性疾病、移植排斥等。
• Pyrimidine derivatives
  申请人：Ohshima Etsuo

  公开号：US20060194811A1

  公开（公告）日：2006-08-31

  A pyrimidine derivative represented by Formula (I) wherein Ar represents substituted or unsubstituted aryl, R 1 represents —NR 2 R 3 and wherein R 2 represents a hydrogen atom or substituted or unsubstituted lower alkyl and R 3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, A represents a single bond, Formula (III) wherein m 1 is 0 to 2, n 1 is 0 to 4, a 1 is from 0 to a substitutable number, R 5 represents substituted or unsubstituted lower alkyl, and each R 5 may be the same or different when a 1 is 2 or more), and Q represents —NR 6 R 7 (wherein R 6 and R 7 may be the same or different and each represents a hydrogen atom, a substituted or unsubstituted heteroalicyclic group, a substituted or unsubstituted heteroalicyclic group, substituted or unsubstituted piperidin-4-ylamino, or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof.

  一种以式（I）表示的嘧啶衍生物，其中Ar表示取代或未取代的芳基，R1表示—NR2R3，其中R2表示氢原子或取代或未取代的低级烷基，R3表示取代或未取代的低级烷基、取代或未取代的芳基烷基，A表示单键，式（III）其中m1为0到2，n1为0到4，a1为0到可取代的数目，R5表示取代或未取代的低级烷基，当a1为2或更多时，每个R5可以相同或不同），Q表示—NR6R7（其中R6和R7可以相同或不同，每个表示氢原子、取代或未取代的杂环芳基、取代或未取代的哌啶-4-基氨基或其季铵盐，或其药学上可接受的盐）。
• NEOSORAPHENS
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP3129385A1

  公开（公告）日：2017-02-15
• [EN] NEOSORAPHENS<br/>[FR] NÉOSORAPHÈNES
  申请人：HELMHOLTZ ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH

  公开号：WO2015154883A1

  公开（公告）日：2015-10-15

  The present invention relates to compounds according to general formula (I); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a Thl7-associated inflammatory and/or autoimmune disease.
• Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors
  作者：Pauline C Ting、Joe F Lee、John C Anthes、Neng-Yang Shih、John J Piwinski

  DOI：10.1016/s0960-894x(00)00702-2

  日期：2001.2

  The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.